Showing results (931-940 of 1,795) with videos related to
Sort By:
Pageof 180
Mabs|February 14, 2023
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-lifeEmma Davé, Oliver Durrant, Neha Dhami, et al.Mabs|November 12, 2016
The TGF-β inhibitory activity of antibody 37E1B5 depends on its H-CDR2 glycanPing Tsui, Daniel R Higazi, Yanli Wu, et al.Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.Mabs|March 22, 2017
Transmembrane TNF-dependent uptake of anti-TNF antibodiesArun Deora, Subramanya Hegde, Jacqueline Lee, et al.Mabs|March 16, 2017
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilarSeokkyun Kim, Jinsu Song, Seungkyu Park, et al.Mabs|March 17, 2017
Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1Dong Li, Jianqing Xu, Zhuozhi Wang, et al.Mabs|March 30, 2017
A new anti-mesothelin antibody targets selectively the membrane-associated formKamal Asgarov, Jeremy Balland, Charline Tirole, et al.Mabs|March 28, 2017
A modular and adaptive mass spectrometry-based platform for support of bioprocess development toward optimal host cell protein clearanceDonald E Walker, Feng Yang, Joseph Carver, et al.Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.Mabs|April 10, 2014
Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, FranceAudrey Guillon-Munos, Arnaud Daguet, Hervé WatierPageof 180